AAV Reference (byproduct-empty)
AAV13 Reference (Byproduct-Empty)
AAV13 Reference (Byproduct-Empty)
AAV13 Reference (Byproduct-Empty)
  1. AAV Reference (byproduct-empty)
  2. AAV13 Reference (Byproduct-Empty)
  3. AAV13 Reference (Byproduct-Empty)
  4. AAV13 Reference (Byproduct-Empty)

AAV13 Reference (Byproduct-Empty)

Price range: $299.00 through $1,799.00

AAV13 Reference (Byproduct-Empty) particles are byproducts of  regular AAV13-CMV-EGFP-2.8kb vectors produced with our pAAVone-AAV13-CMV-EGFP-2.8kb plasmid. Unlike AAV truly-empty particles, AAV byproduct-empty particles may contain partial or incomplete genomes [Wang et al., 2016]. They are not completely devoid of genetic material, and this genetic content can vary in terms of completeness. Byproduct-empty AAV particles are not the primary focus of production and can sometimes be considered impurities or contaminants in the final AAV vector preparation.

  • SKU: DF001001-AAV13
  • AAV Serotype: AAV13
  • AAV Capsid titer: 1.0×1013 VP/ml (VP: Viral Particle) by Elisa
  • Used cell line: HEK 293T
  • Used plasmid: pAAVone-AAV13-CMV-EGFP-2.8kb
  • AAV Genome: AAV-CMV-SV40I-EGFP-WPRE-hGHpolyA-2.8kb
  • Production system: AAVone® [Yang et al., 2025]
  • Purification: AAVx followed by one round of CsCl ultracentrifuge.
  • Buffer: 0.001% F-68/DPBS with additional 150mM NaCl.
  • Endotoxin: <1.o EU/1.0×1013 VP
  • Storage: -80°C for long term (> 1 year);  -20°C for short term(1-2 months);  4 °C for 1-2 weeks..
  • Shipping: Dry ice.
Add to Quote
SKU: DF001001-AAV13 Categories: , Tag:

AAV References at AAVnerGene:

AAV references (Full) and AAV references (Byproduct-Empty) are generated using the AAVone system, with the corresponding pAAVone plasmids carrying a 2.8 kb AAV-CMV-SV40I-EGFP-WRRE-hGHpolyA genome. AAV references (Truly-Empty) are produced by transfection of a single mini-pHelper-AAV plasmid with the corresponding serotypes. AAV reference materials are available for various serotypes, including AAV1, AAV2, AAV3B, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, AAV12, AAV13, AAVrh.74, AAV2-Retro, AAV-DJ, and AAV-PHP.eB.

AAV References Serotype Genome Production Plasmids
 AAV References-2.8kb AAV1, AAV2, AAV3B, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, AAV12, AAV13, AAVrh.74, AAV2-Retro, AAV-DJ, and AAV-PHP.eB Full of AAV-CMV-SV40I-EGFP-WPRE-hGHpolyA-2.8kb pAAVone-AAVs-CMV-EGFP-2.8kb
 AAV References-4.3kb AAV1, AAV2, AAV3B, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, AAV12, AAV13, AAVrh.74, AAV2-Retro, AAV-DJ, and AAV-PHP.eB Full of AAV-CMV-SV40I-EGFP-WPRE-hGHpA-4.3kb pAAVone-AAVs-CMV-EGFP-4.3kb
AAV References (Truly-Empty) AAV1, AAV2, AAV3B, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, AAV12, AAV13, AAVrh.74, AAV2-Retro, AAV-DJ, and AAV-PHP.eB No mini-pHelper-AAVs
AAV References (Byproduct-Empty) AAV1, AAV2, AAV3B, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh.10, AAV11, AAV12, AAV13, AAVrh.74, AAV2-Retro, AAV-DJ, and AAV-PHP.eB Partial of AAV-CMV-SV40I-EGFP-WPRE-hGHpolyA-2.8kb pAAVone-AAVs-CMV-EGFP-2.8kb

Usage of Empty AAV particles: 

Empty AAV particles  can serve as valuable tools for various stages of gene therapy development and characterization.

  1. Reference Materials: Well-characterized empty AAV capsids, can serve as standardized reference materials for analytical assays.
  2. Quality Control: During the manufacturing process of AAV vectors, using well-characterized capsids as reference materials allows manufacturers to monitor and ensure the quality, purity, and consistency of their AAV products.
  3. Biodistribution Studies: Empty AAV can be used in biodistribution studies to assess how different capsids distribute in various tissues after administration.
  4. Immunogenicity Assessment: By exposing the immune system to well-characterized AAV capsids, researchers can evaluate the immune responses induced by specific serotypes..
  5. Comparative Studies: Empty AAV allow researchers to compare the characteristics of different AAV serotypes without the confounding effects of transgene expression.
  6. Process Development: Empty AAV can be used in the development and optimization of manufacturing processes for AAV vectors.
  7. Assay Development: Empty AAV capsids serve as positive controls in various assays, aiding the development of new methods for AAV characterization, stability testing, and potency determination.
  8. Gene Therapy Capsid Decoys: The presence of an excess of empty AAV capsids may effectively absorb low-level neutralizing antibodies (NAbs) and non-NAbs, permitting transduction even in their presence.

References:

Wang Q, et al., Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors. Mol Ther Methods Clin Dev. 2016 Dec 24;4:149-158. doi: 10.1016/j.omtm.2016.12.004. eCollection 2017 Mar 17. PMID:28345000

Yang et al., AAVone: A Cost-Effective, Single-Plasmid Solution for Efficient AAV Production with Reduced DNA Impurities.

Volume Size

100 μL, 200 μL, 500 μL, 1000 μL

Related products